Targeting Non-Small Cell Lung Cancer
The FDA approved a new molecularly targeted therapeutic for certain patients with lung cancer driven by a mutation in...
The FDA approved a new molecularly targeted therapeutic for certain patients with lung cancer driven by a mutation in...
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast...
The first molecularly targeted therapeutic for use in the treatment of bile duct cancer has been approved by the...
The FDA has approved a chemotherapy gel for treating certain patients with cancer of the upper urinary tract. he...
The FDA has approved a molecularly targeted therapeutic for treating certain patients with neurofibromatosis type 1 who have inoperable...
The FDA has approved a new combination of molecularly targeted therapeutics for treating metastatic colorectal cancer with a BRAF...
The FDA has approved a new combination of immunotherapy and chemotherapy as an initial treatment for extensive-stage small cell...
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with...
The FDA has approved the immunotherapeutic isatuximab-irfc (Sarclisa) to treat certain patients with multiple myeloma. The U.S. Food and...